Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Sana Biotechnology, Inc. | EVP & President, R&D | Restricted Stock Units | 67.1K | $369K | $5.50 | Mar 7, 2024 | Direct |
Sana Biotechnology, Inc. | EVP & President, R&D | Stock Option (Right to Buy) | 302K | Mar 7, 2024 | Direct | ||
Codiak BioSciences, Inc. | President & CEO, Director | Common Stock | 7.66K | Mar 28, 2023 | Direct | ||
Climb Bio, Inc. | Director | Stock Option (Right to Buy) | 6.29K | Nov 11, 2024 | Direct | ||
Ovid Therapeutics Inc. | Director | Stock Option (Right to Buy) | 1.75K | May 17, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
CLYM | Climb Bio, Inc. | Nov 11, 2024 | 2 | $0 | 4 | Nov 12, 2024 | Director |
CLYM | Climb Bio, Inc. | Nov 8, 2024 | 0 | $0 | 3 | Nov 12, 2024 | Director |
SANA | Sana Biotechnology, Inc. | Mar 7, 2024 | 2 | $0 | 4 | Mar 8, 2024 | EVP & President, R&D |
SANA | Sana Biotechnology, Inc. | Nov 2, 2023 | 1 | $0 | 4 | Nov 3, 2023 | EVP & President, R&D |
SANA | Sana Biotechnology, Inc. | Apr 10, 2023 | 1 | $0 | 4 | Apr 11, 2023 | EVP & President, R&D |
SANA | Sana Biotechnology, Inc. | Apr 10, 2023 | 0 | $0 | 3 | Apr 11, 2023 | EVP & President, R&D |
CDAKQ | Codiak BioSciences, Inc. | Mar 28, 2023 | 1 | -$7.5K | 4 | Mar 30, 2023 | President & CEO, Director |
CDAKQ | Codiak BioSciences, Inc. | Jan 24, 2023 | 1 | $0 | 4 | Jan 26, 2023 | President & CEO, Director |
CDAKQ | Codiak BioSciences, Inc. | Jan 19, 2023 | 3 | -$2.92K | 4 | Jan 23, 2023 | President and Chief Executive Officer, Director |
CDAKQ | Codiak BioSciences, Inc. | Aug 16, 2022 | 6 | -$20.3K | 4 | Feb 21, 2023 | President & CEO, Director |
CDAKQ | Codiak BioSciences, Inc. | Feb 16, 2022 | 2 | $0 | 4 | Feb 18, 2022 | President & CEO, Director |
CDAKQ | Codiak BioSciences, Inc. | Jan 19, 2022 | 2 | $0 | 4 | Jan 21, 2022 | President & CEO |
OVID | Ovid Therapeutics Inc. | May 17, 2021 | 1 | $0 | 4 | May 18, 2021 | Director |